Cerebral	cerebral	O	B_disease
sinus	sinus	O	I_disease
thrombosis	thrombosis	O	S_disease
as	as	O	O
a	a	O	O
potential	potential	O	O
hazard	hazard	O	O
of	of	O	O
antifibrinolytic	antifibrinolytic	O	O
treatment	treatment	O	O
in	in	O	O
menorrhagia	menorrhagia	O	O
.	.	O	O

We	we	O	O
describe	describe	O	O
a	a	O	O
42-year-old	42-year-old	O	O
woman	woman	O	O
who	who	O	O
developed	developed	O	O
superior	superior	O	O
sagittal	sagittal	O	O
and	and	O	O
left	left	O	O
transverse	transverse	O	O
sinus	sinus	O	O
thrombosis	thrombosis	O	S_disease
associated	associated	O	B_disease
with	with	O	I_disease
prolonged	prolonged	O	O
epsilon-aminocaproic	epsilon-aminocaproic	B_chemical	O
acid	acid	I_chemical	O
therapy	therapy	O	O
for	for	O	O
menorrhagia	menorrhagia	O	O
.	.	O	O

This	this	O	O
antifibrinolytic	antifibrinolytic	O	O
agent	agent	O	O
has	has	O	O
been	been	O	O
used	used	O	O
in	in	O	O
women	women	O	O
with	with	O	O
menorrhagia	menorrhagia	O	O
to	to	O	O
promote	promote	O	O
clotting	clotting	O	O
and	and	O	O
reduce	reduce	O	O
blood	blood	O	B_disease
loss	loss	O	I_disease
.	.	O	O

Although	although	O	O
increased	increased	O	O
risk	risk	O	O
of	of	O	O
thromboembolic	thromboembolic	O	B_disease
disease	disease	O	I_disease
has	has	O	O
been	been	O	O
reported	reported	O	O
during	during	O	O
treatment	treatment	O	O
with	with	O	O
epsilon-aminocaproic	epsilon-aminocaproic	B_chemical	O
acid	acid	I_chemical	O
,	,	O	O
cerebral	cerebral	O	B_disease
sinus	sinus	O	I_disease
thrombosis	thrombosis	O	S_disease
has	has	O	O
not	not	O	O
been	been	O	O
previously	previously	O	O
described	described	O	O
.	.	O	O

Careful	careful	O	O
use	use	O	O
of	of	O	O
epsilon-aminocaproic	epsilon-aminocaproic	B_chemical	O
acid	acid	I_chemical	O
therapy	therapy	O	O
is	is	O	O
recommended	recommended	O	O
.	.	O	O

